Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
8-pCPT-2-OMe-cAMP
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
8-pCPT-2-OMe-cAMP (also known as 007) is a synthetic, cell-permeable analog of cyclic adenosine monophosphate (cAMP) that acts as a potent and highly selective agonist for the exchange proteins directly activated by cAMP, EPAC1 (RAPGEF3) and EPAC2 (RAPGEF4). Unlike endogenous cAMP, 8-pCPT-2-OMe-cAMP selectively activates EPAC signaling pathways without activating protein kinase A (PKA) at typical working concentrations. It is widely utilized as a pharmacological research tool to elucidate PKA-independent cAMP signaling mechanisms in various physiological and pathological processes, including endothelial barrier function, insulin secretion, and cardiac remodeling. In preclinical models, pharmacological activation of EPAC1 with 8-pCPT-2-OMe-cAMP has demonstrated protective effects against the progression of glomerulonephritis and chronic kidney disease by promoting cellular energy adaptations and a glycolytic metabolic shift in podocytes.
- Other names
- 0078-(4-Chlorophenylthio)-2'-O-methyladenosine-3',5'-cyclic monophosphate8-CPT-2Me-cAMP8-pCPT-2'-O-Me-cAMP8-pCPT-2'-OMe-cAMP8-pCPT-2-O-Me-cAMP
02
Targets
EPAC1 (Rap guanine nucleotide exchange factor 3)EPAC2 (Rap guanine nucleotide exchange factor 4)
Beyond the preview
Go deeper on 8-pCPT-2-OMe-cAMP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 8-pCPT-2-OMe-cAMP.